Alkermes’ Richard Pops to Step Down After Three-Decade Run as CEO

Why It Matters

The CEO transition signals a strategic push into high‑margin sleep medicines, a move that could reshape Alkermes’ growth trajectory and investor confidence.

Key Takeaways

• Pops steps down after 32 years as Alkermes CEO
• Blair Jackson, COO, will assume CEO role July 31
• Alkermes pivots toward sleep medicines and orexin drugs
• 2025 profit $242M on $1.5B revenue; 2026 loss forecast
• Shares dropped up to 8% on leadership announcement

Pulse Analysis

After more than three decades at the helm, Richard Pops will leave the CEO chair of Alkermes on July 31, handing the reins to Chief Operating Officer Blair Jackson. Pops, who joined the company in 1991, guided it from a niche drug‑delivery firm to a biopharma with commercial products for schizophrenia, bipolar disorder and addiction. His departure marks the end of one of the longest tenures in biotech, but he will stay on as board chair, ensuring continuity while the new leadership prepares for the next growth phase. Jackson’s appointment coincides with Alkermes’ strategic pivot toward sleep disorders and orexin‑targeted therapies, areas the company believes can become blockbuster revenue streams.

The firm recently closed its acquisition of Avadel Pharmaceuticals, adding the narcolepsy candidate Lumryz and expanding its pipeline in the highly competitive sleep‑medicine market. Late‑stage testing for a narcolepsy drug is slated for this quarter, and the orexin program is being positioned as a long‑term growth engine. This focus on high‑margin, differentiated products aims to offset past setbacks in oncology and earlier CNS attempts.

8 billion. The anticipated increase in inventory and IP costs from the Avadel deal is a primary driver of the near‑term earnings dip. Investors reacted sharply, with the stock sliding up to 8 % on the leadership news. Analysts view the CEO transition as a potential catalyst for renewed confidence, provided the sleep‑medicine rollout delivers the projected upside.